New investigational drug for treatment of ovarian cancer

Trial ID:
IRB-25-8585
Jo Marie Tran Janco, MD

Inclusion Criteria

Patients must:

  • Be 18 years old or older
    Have histological confirmed diagnosis of epithelial high-grade ovarian, fallopian tube, or primary peritoneal carcinoma
    Be newly diagnosed FIGO Stage III or IV
    Have adequate tumor tissue sample available for testing

Exclusion Criteria

Patients must not:

  • Have a BRCA mutation
    Be pregnant or breastfeeding
    Have evidence of ongoing bowel obstruction
    Have anu autoimmune disorders
    Have evidence of bleeding diathesis

Additional Info

All treatments and physical visit during this study will take place at Prebys Cancer Center in Hillcrest.

NCT #06819007

Study duration is expected to occur over 20 months.

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org